MAM
DAN India bags two golds at 9th Global Customer Engagement Award
MUMBAI: Dentsu Aegis Network (DAN) India has emerged victorious at the 9th edition of the ACEF Global Customer Engagement Awards. While Vizeum India, the media agency from the house of DAN, has bagged a Gold for HDFC Bank’s ‘Ek Festival Aisa Bhi’ campaign, digital marketing agency iProspect India has brought home a Gold and a Silver for Angel Broking’s ‘Smart Sauda’ campaign.
Vizeum India CEO Himanka Das said, “This is the result of some remarkable team effort. We are thankful to our client HDFC Bank for their support and for constantly pushing us to create gold standard in what we do.”
Vizeum India senior vice president (west) Kaushik Chakraborty added, “We are extremely happy for our work being recognised as best-in-class. Awards have always been a testimony to recognising good work and motivates teams to push their own benchmark.”
iProspect India EVP operations Muddassar Memon said, “I would like to congratulate the team and our client Angel Broking on the wins. The use of our proprietary tools for the campaign helped us reach the right TG on the right platform and made the campaign a success. It is always heartening to see the work getting acknowledged and awarded.”
For the record, the Global Customer Engagement Awards celebrates the best-of-the-best in Customer Engagement Solutions across various categories within the industry. It also recognises the Best Campaigns, Creatives and Activities executed by Agencies, Media Houses and Brands for customer engagement through various mediums of marketing.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
